Some estimates suggest that 10 percent of the world’s population suffers from various chronic neuropathic pain. Scientists have been conducting studies for a long time for the specific treatment of this disease, which millions of people suffer from. Scientists from the University of Copenhagen, who have been working for 10 years to treat chronic neuropathic pain, have succeeded in a new peptide they’ve developed. Animal tests of the developed peptide show that the compound was successful. But human tests will show the exact success of the compound. Medicines available for chronic pain could not be used effectively due to their side effects For chronic neuropathic pain, drugs such as opioids or anticonvulsants such as gabioentin were previously used. However, other side effects of the drug user and the damage of the drugs to the somatosensor nervous system caused the doctors to be cautious about these drugs. In addition to the severe side effects of the previously used drugs, in other drug development studies, the nervous system was generally slowed down rather than targeting the nerve region that specifically caused the pain. This was the cause of the side effects. New compound targets right nerve region Scientists from the University of Copenhagen have developed the peptide called Tat-P4- (C5) 2 for use in the treatment of chronic neuropathic pain. The newly developed peptide shows that it is possible to prevent the effect of hypersensitive receptors in the patient’s nerve-only nerve region. One of the researchers, Kenneth Lindegaard Madsen, said they have been working for more than 10 years to treat chronic neuropathic pain. In this 10-year period, Madsen says that they have worked on many things, from understanding the biology of the disease to inventing and designing the compound that will work in its treatment. The process has now gone to another stage with the compound’s success in animal testing. The published article on the development of the new compound describes the results of the peptide in animal models designed to simulate neuropathic pain. Experimental treatment did not only affect a large area of the nervous system, but also reduced pain responses. Madsen added that the compound developed for the treatment of chronic pain works very efficiently and does not have any observed side effects at the moment. After success in animal testing, researchers are now working to obtain human tests and patents of the compound. Mass production of the compound will be started after human tests are successful as researchers hope. The compound, which has been successful in treating chronic pain, has also worked to reduce the cocaine search behavior of mice. Therefore, scientists think that the compound can potentially be used in addiction treatment.
